NextPoint Therapeutics, Inc.

NextPoint’s Chief Scientific Officer Tatiana Novobrantseva will be leading the discussion, “Immunoengineering-Enabling Technology” at the upcoming The Drug Carriers in Medicine and Biology Gordon Research Conference. Not attending the meeting? Be sure to visit nextpointtx.com to learn how the company is launching a new world of precision immuno-oncology and tumor-targeting therapeutics through its leading scientific work on the novel B7-H7/HHLA2 axis.

#ICYMI, be sure to check out the poster @NextPoint presented at CIMT in May: “Targeting B7-H7-mediated immunosuppression with NPX267 and NPX887, two fully humanized monoclonal antibodies that target KIR3DL3 and B7-H7, respectively” For more information on how NextPoint’s new class of therapeutics may improve treatment options for cancer patients who do not respond to PD-1/L1 therapy, visit: nextpointtx.com.  

Chief Medical Officer Leena Gandhi spoke last week at the Next-Gen Immuno-Oncology Conference in Boston about NextPoint Therapeutics, Inc.'s novel class of therapeutics targeting the B7-H7 pathway to improve treatment options for cancer therapy. For more information on NextPoint’s new class of therapeutics to improve treatment options for cancer patients who do not respond to PD-1/L1 therapy, visit: nextpointtx.com.  

We are thrilled to announce that our CEO, Ivan Cheung, will be speaking at the Longwood Healthcare Leaders Spring MIT event! Join us for two days of discussion and networking with biopharmaceutical leaders. Co-hosted by Koch Institute Professors Phil Sharp and Bob Langer and held at MIT’s Koch Institute, June 17-18, 2024. https://lnkd.in/exxKDits Longwood Healthcare Leaders Longwood Fund #longwoodhealthcareleaders

Our Chief Scientific Officer, Dr. Tatiana Novobrantseva, took center stage last week at the PEGS Boston conference where she delivered an insightful keynote, “B7-H7 - A Novel Checkpoint Axis and Tumor-Associated Antigen.” NextPoint is advancing a pipeline of immunomodulatory and tumor targeted therapeutics utilizing the B7-H7 (HHLA2) pathway.  Learn more about our science at https://lnkd.in/eZGx_s_A.

CEO Ivan Cheung was honored to attend the #TIME100 Impact Dinner which honored individuals influencing the future of health. Congratulations to all the visionary leaders on the @TIME 100 Health List this year. Under Ivan’s leadership, NextPoint is advancing a new class of precision immuno-oncology and tumor-directed therapeutics targeting the novel B7-H7 axis, so that we can improve treatment options for cancer patients including those who do not benefit from PD-1/L1 therapy. Read more: nextpointtx.com

As we continue to push the boundaries of possibility, we are immensely grateful to be part of the LabCentral community. LabCentral is the heart of our innovation and we're excited to share the impressive success of LabCentral and their 2023 Impact Report. https://lnkd.in/eAxUk4T3 LabCentral has state-of-the-art facilities with access to top-tier resources where brilliant minds come together and make magic every day. #Innovation #Collaboration #LabCentral #Science #Technology #Research

We are proud to share that our CEO Ivan Cheung has been named to the 2024 #TIME100HEALTH list by TIME, which recognizes the 100 most influential people in global health. “Ivan has demonstrated a relentless commitment to translating scientific breakthroughs into tangible solutions that benefit patients worldwide. The well-deserved recognition by TIME underscores his outstanding contributions to public health and exemplifies his visionary leadership and unwavering dedication to improving the lives of patients.” - Detlev Biniszkiewicz, PhD, Managing Director at MPM BioImpact and Chairman of NextPoint’s Board of Directors. Under Ivan’s leadership, NextPoint is advancing a new class of precision immuno-oncology and tumor-directed therapeutics targeting the novel B7-H7 axis, so that we can improve treatment options for cancer patients including those who do not benefit from PD-1/L1 therapy. Read the full announcement at https://nextpointtx.com/. 

We are thrilled to share that our company had the incredible opportunity to volunteer at Community Servings. Community Servings is a remarkable organization dedicated to providing nutritious meals to individuals and families facing critical and chronic illnesses. Their mission deeply resonates with our values at NextPoint Therapeutics and we are honored to contribute to their impactful work. NextPoint had the chance to roll up our sleeves and get involved in various activities, from meal preparation to packaging. It was inspiring to see firsthand the dedication and passion of the Community Servings team and the positive impact they make on the lives of so many. A huge thank you to Community Servings for welcoming us with open arms and for the amazing work they do every day. #communityservice #volunteering #makingadifference #communityservings #teamwork

Congratulations to NextPoint co-founder Dr. Gordon Freeman!